{"id":"sox-plus-pd-1-inhibitor","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Immune-related adverse events (fatigue, rash, hepatotoxicity)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SOX is a chemotherapy regimen (S-1 and oxaliplatin) that directly damages cancer cell DNA and triggers cell death. The PD-1 inhibitor removes immune checkpoint inhibition, allowing T cells to recognize and attack cancer cells more effectively. This combination leverages both direct cytotoxicity and immune activation for enhanced anti-tumor efficacy.","oneSentence":"SOX chemotherapy combined with a PD-1 inhibitor uses cytotoxic drugs to kill cancer cells while simultaneously blocking PD-1 to enhance anti-tumor immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:08:57.157Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer or gastroesophageal junction cancer (likely primary indication based on SOX use)"}]},"trialDetails":[{"nctId":"NCT07401199","phase":"","title":"Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)","status":"NOT_YET_RECRUITING","sponsor":"Qun Zhao","startDate":"2026-02-05","conditions":"Gastric Cancer (GC), Locally Advanced Gastric Cancer","enrollment":2000},{"nctId":"NCT07263386","phase":"PHASE2","title":"A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-10-23","conditions":"Gastric Adenocarcinoma","enrollment":460},{"nctId":"NCT07178340","phase":"PHASE2","title":"Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-09-18","conditions":"Hepatoid Adenocarcinoma of Stomach","enrollment":30},{"nctId":"NCT07072351","phase":"PHASE1, PHASE2","title":"Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-09-15","conditions":"Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy","enrollment":88},{"nctId":"NCT06826079","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-11-01","conditions":"Gastric Junction Adenocarcinoma, Gastric Cancer, Immunotherapy","enrollment":80},{"nctId":"NCT07161453","phase":"PHASE4","title":"Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2025-09-30","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":500},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":"Gastric Adenocarcinoma, Stomach Neoplasms","enrollment":54},{"nctId":"NCT07149181","phase":"PHASE4","title":"Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2025-08-31","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":1000},{"nctId":"NCT07132528","phase":"PHASE4","title":"Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2025-08-31","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":1000},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT07056010","phase":"NA","title":"Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-11-25","conditions":"Gastric Cancer","enrollment":30},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT05170503","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-12-29","conditions":"Esophagogastric Junction Adenocarcinoma","enrollment":37},{"nctId":"NCT06963593","phase":"PHASE4","title":"Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2025-06-01","conditions":"Advanced Gastroesophageal Cancer","enrollment":220},{"nctId":"NCT06888037","phase":"PHASE2","title":"Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-03-31","conditions":"Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy","enrollment":55},{"nctId":"NCT06464601","phase":"","title":"A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Wuhan University","startDate":"2025-04-01","conditions":"Gastric Cancer","enrollment":70},{"nctId":"NCT06250894","phase":"PHASE2","title":"Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-03-30","conditions":"PD-1, Neoadjuvant Chemoradiotherapy, Gastroesophageal Junction Cancer","enrollment":32},{"nctId":"NCT06202781","phase":"","title":"Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2022-07-01","conditions":"Gastric Cancer, Tumor Microenvironment, Immunotherapy","enrollment":28},{"nctId":"NCT06158919","phase":"NA","title":"A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-11-20","conditions":"Gastric Cancer/Adenocarcinoma of Esophagogastric Junction","enrollment":58},{"nctId":"NCT05970627","phase":"PHASE2","title":"Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Yu jiren","startDate":"2023-07-28","conditions":"Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma","enrollment":30},{"nctId":"NCT04890392","phase":"PHASE2","title":"Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-01-15","conditions":"Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":20},{"nctId":"NCT04997837","phase":"PHASE3","title":"Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-07-21","conditions":"Gastric Cancer","enrollment":433},{"nctId":"NCT04913896","phase":"","title":"CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2021-06-01","conditions":"Gastric Cancer, Magnetic Resonance Imaging, Tomography, X-Ray Computed","enrollment":200},{"nctId":"NCT04908566","phase":"PHASE2","title":"Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-05","conditions":"Locally Advanced Gastric Adenocarcinoma","enrollment":124}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"SOX plus PD-1 inhibitor","genericName":"SOX plus PD-1 inhibitor","companyName":"Liaoning Cancer Hospital & Institute","companyId":"liaoning-cancer-hospital-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SOX chemotherapy combined with a PD-1 inhibitor uses cytotoxic drugs to kill cancer cells while simultaneously blocking PD-1 to enhance anti-tumor immune responses. Used for Gastric cancer or gastroesophageal junction cancer (likely primary indication based on SOX use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}